Serum concentration of dantrolene and its active metabolite, 5-hydroxydantrolene were determined in 27 cerebral palsy patients. Correlation coefficients between the oral dose of dantrolene and serum levels of dantrolene and its major metabolite, 5-hydroxydantrolene were rather small in cerebral palsy patients. The mean half-times of dantrolene and 5-hydroxydantrolene were 3.41 (n = 6) and 4.00 (n = 5) hours, respectively. These values were about a half of those reported earlier Lietman et al., 1974; Meyler et al., 1979; Flewellen et al., 1983. The poor correlation between serum level and dose may be due to the variation in an extent of oral dantrolene availability.
%0 Journal Article
%1 Inotsume1986
%A Inotsume, N.
%A Higashi, A.
%A Matsukane, I.
%A Chikazawa, S.
%A Nakano, M.
%A Matsuda, I.
%D 1986
%J Pediatr Pharmacol (New York)
%K Adolescent; Adult; Cerebral Palsy; Child; Child, Preschool; Dantrolene; Dose-Response Relationship, Drug; Female; Humans; Kinetics; Male; Metabolic Clearance Rate
%N 4
%P 253--259
%T Relationship between serum concentration and daily dose of dantrolene in cerebral palsy patients.
%V 5
%X Serum concentration of dantrolene and its active metabolite, 5-hydroxydantrolene were determined in 27 cerebral palsy patients. Correlation coefficients between the oral dose of dantrolene and serum levels of dantrolene and its major metabolite, 5-hydroxydantrolene were rather small in cerebral palsy patients. The mean half-times of dantrolene and 5-hydroxydantrolene were 3.41 (n = 6) and 4.00 (n = 5) hours, respectively. These values were about a half of those reported earlier Lietman et al., 1974; Meyler et al., 1979; Flewellen et al., 1983. The poor correlation between serum level and dose may be due to the variation in an extent of oral dantrolene availability.
@article{Inotsume1986,
abstract = {Serum concentration of dantrolene and its active metabolite, 5-hydroxydantrolene were determined in 27 cerebral palsy patients. Correlation coefficients between the oral dose of dantrolene and serum levels of dantrolene and its major metabolite, 5-hydroxydantrolene were rather small in cerebral palsy patients. The mean half-times of dantrolene and 5-hydroxydantrolene were 3.41 (n = 6) and 4.00 (n = 5) hours, respectively. These values were about a half of those reported earlier [Lietman et al., 1974; Meyler et al., 1979; Flewellen et al., 1983]. The poor correlation between serum level and dose may be due to the variation in an extent of oral dantrolene availability.},
added-at = {2014-07-19T20:29:36.000+0200},
author = {Inotsume, N. and Higashi, A. and Matsukane, I. and Chikazawa, S. and Nakano, M. and Matsuda, I.},
biburl = {https://www.bibsonomy.org/bibtex/2c5f17f1e5b9ad52ef796b6df58d720af/ar0berts},
groups = {public},
interhash = {e83e8defeaa5838541e85278d8318a6d},
intrahash = {c5f17f1e5b9ad52ef796b6df58d720af},
journal = {Pediatr Pharmacol (New York)},
keywords = {Adolescent; Adult; Cerebral Palsy; Child; Child, Preschool; Dantrolene; Dose-Response Relationship, Drug; Female; Humans; Kinetics; Male; Metabolic Clearance Rate},
number = 4,
pages = {253--259},
pmid = {3737270},
timestamp = {2014-07-19T20:29:36.000+0200},
title = {Relationship between serum concentration and daily dose of dantrolene in cerebral palsy patients.},
username = {ar0berts},
volume = 5,
year = 1986
}